The molecules which are utilized for optimizing the blood sugar like GLP-1 RAs and others have to undergo Cardiovascular outcome clinical trials (CVOTs). The trail is destined to showcase cardiovascular safety of these molecules.

Trails take place on the grounds of the establishment of cardiovascular superiority or inferiority of the molecule. In this exclusive interview, various aspects of CVOTs with GLP analogues have been thoroughly discussed.